tiprankstipranks
Perrigo announces FDA rescheduled meeting to review application for Opill
The Fly

Perrigo announces FDA rescheduled meeting to review application for Opill

Perrigo Company announced that the FDA has rescheduled a joint meeting of the Nonprescription Drugs Advisory Committee, or NDAC, and the Obstetrics, Reproductive, and Urologic Drugs Advisory Committee, or ORUDAC, for May 9 & 10, to review the Company’s application for Opill daily oral contraceptive for over-the-counter, or OTC, use. Perrigo announced in July 2022 that its HRA Pharma affiliate filed an application with the FDA for the Rx-to-OTC switch of Opill, a progestin-only daily birth control pill.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on PRGO:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles